•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Vertex Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
What Vertex (VERX) Said on Its Q3 Earnings Call
Vertex, Inc. (VERX) Q3 2026 Earnings Call Transcript
Vertex (VERX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Vertex (VERX) Surpasses Q3 Earnings and Revenue Estimates
Vertex Announces Third Quarter 2026 Financial Results
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion
Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results
Vertex Pharmaceuticals Q3 Earnings Call Highlights
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction
Vertex Reports Third Quarter 2026 Financial Results
Asure Software and Vertex Announce Strategic Alliance to Expand Payroll Tax Management Reach
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Vertex Introduces Vertex Sōl™, a Connected, AI-Powered Tax and Compliance Experience
The $500 Million Non-CF Factor Vertex Investors Can't Ignore on Nov. 2
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III
Vertex, Inc. (NASDAQ:VERX) Stock Has Average Price Target of $17.50
Vertex Appoints Daniel Brennan to its Board of Directors